http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
류마티스관절염 활막세포에서 Peroxisome Proliferator-activated Receptor-γ Agonist 처치의 염증매개인자 감소 및 활막세포 증식의 억제효과
권용진 ( Yong Jin Kwon ),정수진 ( Soo Jin Chung ),김태연 ( Tae Yeon Kim ),박민찬 ( Min Chan Park ) 대한류마티스학회 2010 대한류마티스학회지 Vol.17 No.2
Objective: This study investigated the effect of rosiglitazone, a synthetic peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, on pro-inflammatory gene expressions and cellular proliferation of fibroblast like synoviocyte (FLS) from patients with rheumatoid arthritis (RA), and to determine whether these actions are mediated by nuclear factor-kappaB (NF-B) down- regulation. Methods: Synovial tissues from patients with RA were obtained during total knee replacement surgery, and FLS were isolated. RA FLS were subsequently treated with 10 μM, 50 μM and 150 μM rosiglitazone with or without TNF-α (10 ng/mL) stimulation. FLS proliferation in response to rosiglitazone treatment was measured by MTT assay, and mRNA expressions of IL-1β, IL-6, CCL-2, CCL-7, COX-2 and MMP-9 were determined by real-time quantitative RT-PCR. The effects of rosiglitazone on NF-κB activation were evaluated using electrophoretic mobility shift assay (EMSA). Results: Rosiglitazone treatment without TNF-α induced a dose-dependent reduction in mRNA expressions of IL-1β, IL-6, CCL-2, CCL-7, COX-2 and MMP-9 from RA FLS. When TNF-α were treated with rosiglitazone, mRNA expressions of COX-2, MMP-9 were reduced dose- dependently. But mRNA expressions of IL-1β, IL-6, CCL-2, CCL-7 were increased in 10 μM rosiglitazone with TNF-α and then decreased as the concentration of rosiglitazone increased. Rosiglitazone treatment also suppressed FLS proliferation in a dose-dependent manner, and EMSA showed decreased NF-κB expression with rosiglitazone treatment. Conclusion: Rosiglitazone suppressed cellular proliferation and mRNA expressions of pro-inflammatory mediators by down-regulating the NF-κB signaling pathway in RA FLS. The outcomes suggest that activation of PPAR-γ can be a novel therapeutic approach in RA.
증례 : 류마티스 ; Henoch-Schonlein Purpura 환자에서 동반된 폐출혈 1예
권용진 ( Yong Jin Kwon ),정수진 ( Soo Jin Chung ),박민찬 ( Min Chan Park ) 대한내과학회 2011 대한내과학회지 Vol.80 No.6
저자들은 피부 자반증, 복통, 혈변, 단백뇨 및 혈뇨가 발생하여 HSP로 진단된 후 급격한 폐출혈 및 이차성 폐렴이 발생하여 경정맥 항생제투여로 감염 조절 후 부신피질호르몬제 치료를 통해 폐출혈이 회복된 1예를 경험하였기에 문헌고찰과 함께 보고하는 바이다. Henoch-Schonlein purpura (HSP) is an immunologically mediated systemic vasculitis of small blood vessels that primarily involves the skin, gastrointestinal tract, joints, and kidneys. HSP is a relatively common vasculitic syndrome in children, which usually resolves within several weeks, and requires no treatment. The pulmonary parenchymal involvement of HSP is a rare complication that predominantly occurs in adolescents and adults. Mortality following HSP pulmonary presentation is extremely high. Here, we report a case of HSP combined with pulmonary hemorrhage as a presentation of the vasculitic involvement of the lung. Recently, we experienced a case of a 49-year-old male patient with HSP who presented with palpable purpura, enteritis, and glomerulonephritis. Following the diagnosis of HSP, the patient developed sudden pulmonary hemorrhage due to the pulmonary involvement of vasculitis, and recovered following glucocorticoid therapy. (Korean J Med 2011;80:739-744)
권용진(Yong Jin Kwon),정규원(Kyu Won Jeong) 대한기계학회 2018 대한기계학회 춘추학술대회 Vol.2018 No.12
In this paper, a signal processing system of the wheel dynamometer is studied. The wheel dynamometer is a sensor for measuring 6-components of load load which consists of 3 forces(Fx, Fy, Fz) and 3 moments(Mx, My, Mz) in real time while a vehicle is driving. It has 4 beams that each of those has 4 strain-gages and it is installed on the wheel of a vehicle. For measuring 6-components of load in real time, first of all, 16 strain-gages measure strains very quickly. After measuring strains, the signal processing system calculates the 6-components of load from the strains by an algorithm. The system has a DSP as a processor to calculate them. It also has a Zigbee communication module to deliver the calculated data to external devices which like a computer by wireless.
연구논문(硏究論文) : 의료의 질 향상 및 환자안전을 위한 제도 도입에 관한 고찰
권용진 ( Yong Jin Kwon ),임영덕 ( Young Deok Lim ) 단국대학교 법학연구소 2012 법학논총 Vol.36 No.2
The landmark report "To Err is Human", by the Institute of Medicine in 1999, cited studies that found that at least 44,000 people and potentially as many as 98,000 people die in United States hospitals each year as a result of preventable medical errors. So, medical errors were a big issue in U.S. And U.S. Congress make the legal system for preventing medical errors. The medical mistakes can be prevented by designing and utilizing the medical errors database system through reporting adverse events. But medical providers are reluctant to report their adverse events and participate in quality review activities for fear of liability or injury to their reputations. This problem can cause to prevent the accumulation of a sufficient number of adverse events. But if medical providers have the privilege of exemption from liability when they report their adverse events on the Patient Safety and Quality Improvement Act, report system for the medical errors database system may operate properly. Through a comparative study on the Patient Safety and Quality Improvement Act of foreign countries, we can draw implications for enacting the Patient Safety and Quality Improvement Act in Korea.
건강보험 청구자료를 활용한 약물관련 악골괴사의 국내 현황 및 비용 분석
권용진(Yongjin Kwon),박미혜(Mi-Hai Park) 대한약학회 2020 약학회지 Vol.64 No.4
Although Medication-Related Osteonecrosis of the Jaw (MRONJ) does not usually occur, the use of drugs that may cause MRONJ is increasing and there is no research reported about its cost and the perception of MRONJ is low in Korea. So here we analyzed the current disease status, such as occurrence and duration, and the cost of treatment of MRONJ in Korea. It was analyzed by the National Health Insurance Service sample cohort 2.0DB data. Patients were included who diagnosed and treated with ‘Osteonecrosis due to drugs (ICD-10: M87.1)’ or ‘Inflammatory conditions of jaws (ICD-10: K10.2)’ after the less than three years from the last dose of drugs. A total of 183 MRONJ patients were identified. The most frequently administered Bone-Modifying Agents were Alendronate, Risedronate, and Ibandronate. From 2002 to 2015, the proportion of MRONJ in the total number of prescribed patients was between 0.2% and 0.9%. The billing costs for MRONJ per patient was KRW 934,422. The highest cost claim was Surgery of Osteomyelitis of Mandible or Maxilla. The total cost of medical, non-medical and indirect costs was KRW 1,891,808 per patient. Through this research, it was found that the cost of treatment of MRONJ was high, and it was possible to analyze the current status and characteristics of MRONJ in Korea.